Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Healthy subject of either gender,~2. Age 12 to 18 months ,~3. Consent form signed by both parent(s) or by the legal representative properly informed about the study,~4. Parent(s) / legal representative able to understand the protocol requirements and to fill in the Diary Card.~Exclusion Criteria:~1. Prior receipt of measles, mumps, rubella or varicella vaccine either alone or in combination vaccine,~2. Known or suspected clinical history of infection with measles, mumps, rubella, varicella or zoster,~3. Any recent (≤30 days) exposure to measles, mumps or rubella,~4. Any recent (≤30 days) exposure to varicella or zoster involving:~5. Any recent (≤3 days) history of febrile illness~6. Any severe chronic disease,~7. Active untreated tuberculosis,~8. Known personal history of seizures,~9. Any known blood dyscrasia, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems,~10. Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection,~11. Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed~12. Any recent tuberculin test (≤7 days) or scheduled tuberculin test through visit 2,~13. Any previous (≤150 days) receipt of immune serum globulin or any blood-derived products or scheduled to be administered through visit 2,~14. Any recent receipt of an inactivated or a live vaccine (≤30 days) or scheduled vaccination through visit 2

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).